Company news

Fulcrum Therapeutics, Inc. news in 2021

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

December 5, 2021

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

November 16, 2021

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

November 3, 2021

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

November 2, 2021

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8: 00 a.m. ET

October 27, 2021

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2021

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

September 19, 2021

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

September 7, 2021

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

September 1, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

August 15, 2021

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

August 10, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

August 9, 2021

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

August 9, 2021

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8: 00 a.m. ET

August 3, 2021

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

June 23, 2021

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

June 20, 2021

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

May 11, 2021

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

May 6, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

May 5, 2021

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

May 5, 2021

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8: 00 a.m. ET

April 28, 2021

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

April 8, 2021

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

March 23, 2021

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

March 17, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

March 3, 2021

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8: 00 a.m. ET

February 25, 2021

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

February 25, 2021

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

February 18, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

January 21, 2021

Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

January 18, 2021

Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference

January 5, 2021

Calls in 2021

Decks in 2021